Platelet Count and Major Bleeding in Patients Receiving Vitamin K Antagonists for Acute Venous Thromboembolism, Findings From Real World Clinical Practice.

Détails

ID Serval
serval:BIB_4BCDB161AA2A
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Platelet Count and Major Bleeding in Patients Receiving Vitamin K Antagonists for Acute Venous Thromboembolism, Findings From Real World Clinical Practice.
Périodique
Medicine
Auteur(s)
Giorgi-Pierfranceschi M., Di Micco P., Cattabiani C., Guida A., Pagán B., Morales M.del V., Salgado E., Suriñach J.M., Tolosa C., Monreal M.
Collaborateur(s)
RIETE Investigators
Contributeur(s)
Adarraga M.D., Andújar V., Arcelus J.I., Ballaz A., Barba R., Barrón M., Blanco-Molina A., Casado I., Castejón-Pina N., de Miguel J., del Molino F., del Toro J., Diaz J.A., Falga C., Font L., Gallego P., Garcia- Bragado F., Gómez V., González J., Grau E., Guijarro R., Guirado L., ndez-Blasco L., Hernández- Huerta S., Jara-Palomares L., Jaras M.J., Jiménez D., Lacruz B., Lecumberri R., Lobo J.L., López-Reyes R., Sáez J.B., Lorente M.A., Lorenzo A., Madridano O., Maestre A., Marchena P.J., Martin-Martos F., Monreal M., Morales M.V., Nauffal D., Nieto J.A., Odriozola M., Otero R., Pagán B., Pedrajas J.M., Pérez G., Peris M.L., Pons I., Porras J.A., Riera-Mestre A., Rivas A., Rosa V., Sabio P., Sampériz A., Sánchez R., Sanz O., Soler S., Suriñach J.M., Tiberio G., Tolosa C., Trujillo-Santos J., Uresandi F., Valero B., Valle R., Vela J., Vela L., Vidal G., Vilar C., Villalobos A., Villalta J., Xifre B., Vanassche T., Verhamme P., Wells P., Hirmerova J., Maly R., Salgado E., Bertoletti L., Bura-Riviere A., Farge-Bancel D., Hij A., Mahe I., Merah A., Moustafa F., Schellong S., Babalis D., Papadakis M., Tzinieris I., Braester A., Brenner B., Tzoran I., Apollonio A., Barillari G., Bucherini E., Ciammaichella M., Cola S., Di Micco P., Enea I., Ferrazzi P., Guida A., Lessiani G., Lodigiani C., Maida R., Mastroiacovo D., Pace F., Pasca S., Pesavento R., Pinelli M., Piovella C., Prandoni P., Rota L., Tiraferri E., Tonello D., Tufano A., Visona A., Zalunardo B., Belovs A., Sablinskis K., Skride A., Ribeiro F., Ribeiro J.L., Bosevski M., Zdraveska M., Alatri A., Bounameaux H., Calanca L., Mazzolai L.
ISSN
1536-5964 (Electronic)
ISSN-L
0025-7974
Statut éditorial
Publié
Date de publication
11/2015
Peer-reviewed
Oui
Volume
94
Numéro
47
Pages
e1915
Langue
anglais
Notes
Publication types: Journal Article ; Multicenter Study ; Observational Study ; Research Support, Non-U.S. Gov't
Publication Status: ppublish
Résumé
The outcome of patients with acute venous thromboembolism (VTE) and abnormal platelet count (PlC) at baseline has not been consistently studied. In real-world clinical practice, a number of patients with abnormal PlC receive vitamin K antagonists (VKAs) to treat acute VTE despite their higher risk of bleeding.We used the Registro Informatizado de Enfermedad TromboEmbólica registry database to compare the rate of major bleeding in patients receiving VKA for long-term therapy of acute VTE according to PlC levels at baseline. Patients were categorized as having very low (<100,000/μL), low (100,000-150,000/μL), normal (150,000-300,000/μL), high (300,000-450,000/μL), or very high (>450,000/μL) PlC at baseline.Of 55,369 patients recruited as of January 2015, 37,000 (67%) received long-term therapy with VKA. Of these, 611 patients (1.6%) had very low PlC, 4006 (10.8%) had low PlC, 25,598 (69%) had normal PlC, 5801 (15.6%) had high PlC, and 984 (2.6%) had very high PlC at baseline. During the course of VKA therapy (mean, 192 days), there were no differences in the duration or intensity (as measured by international normalized ratio levels) of treatment between subgroups. The rate of major bleeding was 3.6%, 2.1%, 1.9%, 2.1%, and 3.7%, respectively, and the rate of fatal bleeding was 0.98%, 0.17%, 0.29%, 0.34%, and 0.50%, respectively. Patients with very low or very high PlC levels were more likely to have severe comorbidities.We found a nonlinear "U-shaped" relationship between PlC at baseline and major bleeding during therapy with VKA for VTE. Consistent alteration of PlC values at baseline suggested a greater frailty.
Mots-clé
Aged, Anticoagulants/adverse effects, Anticoagulants/therapeutic use, Female, Fibrinolytic Agents/adverse effects, Fibrinolytic Agents/therapeutic use, Follow-Up Studies, Hemorrhage/chemically induced, Hemorrhage/epidemiology, Humans, International Normalized Ratio, Male, Middle Aged, Platelet Count, Registries, Treatment Outcome, Venous Thromboembolism/drug therapy, Vitamin K
Pubmed
Web of science
Open Access
Oui
Création de la notice
08/05/2020 13:36
Dernière modification de la notice
02/06/2020 14:30
Données d'usage